利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.036 秒)

    Spiro imidazoline compounds
    4.
    发明授权
    Spiro imidazoline compounds 失效
    螺咪唑啉化合物

    公开(公告)号：US06172097B2

    公开(公告)日：2001-01-09

    申请号：US09465619

    申请日：1999-12-17

    申请人： Alex Cordi ,  Mark Millan ,  Adrian Newman-Tancredi ,  Mauricette Brocco

    发明人： Alex Cordi ,  Mark Millan ,  Adrian Newman-Tancredi ,  Mauricette Brocco

    IPC分类号： A61K314184

    CPC分类号： C07D235/02

    摘要： The invention relates to a compound of formula (I): wherein: A represents an optionally substituted benzene ring, B represents an imidazoline ring of formula (Ia) or (Ib): and medicinal products containing the same/are useful in treating or in preventing depression, obesity, panic attacks, anxiety, obsessive-compulsive disorders, cognitive disorders, phobias, impulsive disorders associated with the abuse of drugs and withdrawal therefrom, sexual dysfunctions, and Parkinson's disease.

    摘要翻译： 本发明涉及式（I）化合物：其中：A表示任选取代的苯环，B表示式（Ia）或（Ib）的咪唑啉环：和含有该化合物的药物，可用于治疗或 预防抑郁症，肥胖症，惊恐发作，焦虑症，强迫症，认知障碍，恐怖症，与药物滥用相关的冲动性疾病和从其中退出，性功能障碍和帕金森病。

    Benzopyran compounds as 5-HT.sub.2C receptor antagonists
    9.
    发明授权
    Benzopyran compounds as 5-HT.sub.2C receptor antagonists 失效
    苯并吡喃化合物作为5-HT2C受体拮抗剂

    公开(公告)号：US5723484A

    公开(公告)日：1998-03-03

    申请号：US786504

    申请日：1997-01-21

    申请人： Gilbert Lavielle ,  Thierry Dubuffet ,  Mark Millan ,  Adrian Newman-Tancredi

    发明人： Gilbert Lavielle ,  Thierry Dubuffet ,  Mark Millan ,  Adrian Newman-Tancredi

    IPC分类号： A61K31/40 ,  A61K31/435 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/04 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/26 ,  A61P25/30 ,  A61P43/00 ,  C07D491/04 ,  C07D491/052 ,  C07D491/52

    CPC分类号： C07D491/04

    摘要： Compounds of formula (I): ##STR1## in which: n represents 1 or 2, R.sub.1 represents hydrogen or alkyl, benzyl, acetyl, benzoyl, allyl, pyridinecarbonyl, pyridinemethyl, acylaminoalkyl (optionally substituted), pyridineaminocarbonyl, phthalimidoalkyl, thiochromanyloxyalkyl or (benzodioxanyloxy)alkyl, R.sub.2, R.sub.3 or R.sub.4, which may be identical or different, represent hydrogen or halogen or alkyl, alkoxy, hydroxyl, acetyl, aminocarbonyl, aminomethyl, cyano, nitro, amino, phenyl (which may or may not be substituted), furyl, pyridinyl, thienyl or pyridyl, or alternatively, when they are located on adjacent carbons, R.sub.2 and R.sub.3 form, with the carbon atoms which bear them, a furan or phenyl ring, the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid, and medicinal products containing the same are useful for the treatment of diseases requiring a ligand to the 5-HT.sub.2C receptors.

    摘要翻译： 乙酰基，苯甲酰基，烯丙基，吡啶羰基，吡啶甲基，酰氨基烷基（任意取代的），吡啶氨基羰基，苯二甲酰亚氨基烷基， 可以相同或不同的二氢苯并二氢吡喃基氧基烷基或（苯并二氧代氧基）烷基，R2，R3或R4代表氢或卤素或烷基，烷氧基，羟基，乙酰基，氨基羰基，氨基甲基，氰基，硝基，氨基，苯基（可以或不可以 或呋喃基，吡啶基，噻吩基或吡啶基，或者当它们位于相邻的碳上时，R2和R3与它们携带的碳原子一起形成呋喃或苯环，其异构体及其加成盐 与药学上可接受的酸和含有该药物的药物可用于治疗需要5-HT 2C受体配体的疾病。